Work

Y90-ibritumomab tiuxetan (Y90-IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation (ASCT) for elderly patients with lymphoma in relapse or resistant to chemotherapy: A feasibility trial (SAKK 37/05).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.8560

Authors: Michele Voegeli, Stephanie Rondeau, Simona Berardi, Erika Lerch, Luciano Wannesson, Thomas Pabst, Jochen Rentschler, Mario Bargetzi, Lorenz M. Jost, Nicolas Ketterer, Angelika Bischof Delaloye, Michele E. G. Ghielmini

Institutions: Kantonsspital Baselland, Swiss Group For Clinical Cancer Research, Istituto Oncologico della Svizzera Italiana, University Hospital of Basel, Kantonsspital Aarau, Kantonsspital Baselland Standort Bruderholz, Centre Hospitalier Universitaire Vaudois

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603394063

Cites:

Cited by:

Related to: 10